Explore how large-scale, de-identified real-world datasets enable more representative trial design, improve site selection, ...

In today’s ACT Brief, we look at how FDA policy is accelerating the use of de-identified real-world evidence in clinical ...

In today’s ACT Brief, we look at how global clinical development is evolving through decentralized models and emerging ...

In today’s ACT Brief, we look at why durable signal closure is emerging as a defining metric in risk-based quality management ...

In today’s ACT Brief, we examine why life sciences companies are maintaining DEI commitments amid political pressure, what’s ...

In today’s ACT Brief, we look at efforts to address sex-based evidence gaps in Parkinson’s disease research, why ...

When we think about where AI can help, it’s about reducing administrative burden. Tools like Smart Draft help streamline ...

Meeting sites where they are—within their systems, workflows, and technology—is something we’re deeply interested in ...

Pharma is understandably risk-averse, and many companies remain in pilot mode, running small experiments that never scale.

Traditional clinical trial data are pseudonymized data, and these data may not contain information on a patient that directly identifies them, like a name, address, or phone number. However, ...

Examine the strategies community research sites can use to secure trial opportunities, from adopting AI-enabled workflows to ...

This latest government action impacting the research space would allocate $116.8 billion in 2026 funding to the HHS—an increase of $210 million from 2025. Within the HHS, the National Institutes of ...